SGLT2 inhibitors improved both glycemic control and cognitive function in patients with diabetes and animal models [37,38], likely owing to their anti-inflammatory and antioxidative properties, which also improve insulin resistance and peripheral glucose metabolism [39,40]. The gene discussed is SLC5A2; the disease is diabetes mellitus.